The Patent Finder

Sirnaomics, Inc.

9 patents currently held · Updated Nov 15, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Jan 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 15, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

PatentTitleStatus Expires Confidence
US 9,012,622Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,642,873Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,868,952Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,006,500Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV)
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,054,714Peptide docking vehicle for targeted nucleic acid delivery
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,378,552Oligomeric compound for inhibiting expression of factor XI
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,612,626An siRNA compound that inhibits expression of APOC3
In force
 · High confidence
In forceHigh confidence
US 12,600,967An siRNA compound that inhibits complement factor B (CFB).
In force
 · High confidence
In forceHigh confidence
US 12,685,775Oligonucleotides with Nucleoside Analogs
In force
 · Medium confidence
In forceMedium confidence
Also on record, not counted in the 9: 2 patents in force now held by others · 2 lapsed for an unpaid fee · 1 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 4 abandoned · 24 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited